

Adel Hasan Mansur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6518628/publications.pdf>

Version: 2024-02-01

45
papers

2,142
citations

304743

22
h-index

243625

44
g-index

46
all docs

46
docs citations

46
times ranked

2689
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. <i>European Respiratory Journal</i> , 2022, 59, 2100768.	6.7	8
2	Ethnic Differences in Severe Asthma Clinical Care and Outcomes: An Analysis of United Kingdom Primary and Specialist Care. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 495-505.e2.	3.8	14
3	Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment. <i>Respiratory Medicine Case Reports</i> , 2022, 35, 101559.	0.4	1
4	Mode of onset and triggers of severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 466-467.	1.0	1
5	Associations between employment and sociodemographic and health-related factors in asthmatic patients assessed at a regional severe asthma service. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	3.8	2
6	Burden of allergic disease among ethnic minority groups in high-income countries. <i>Clinical and Experimental Allergy</i> , 2022, 52, 604-615.	2.9	12
7	Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553.	5.6	14
8	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2974-2986.	5.7	11
9	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3362-3376.	5.7	7
10	Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. <i>Thorax</i> , 2021, 76, 220-227.	5.6	83
11	Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 57-68.	10.7	88
12	Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthma. <i>Chronic Respiratory Disease</i> , 2021, 18, 147997312110435.	2.4	11
13	The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference. <i>European Respiratory Journal</i> , 2021, 57, 2100300.	6.7	5
14	Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2691-2701.e1.	3.8	13
15	Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 731-734.	5.6	40
16	Symptom-based questionnaires predict frequent exacerbations in severe asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4480-4482.e1.	3.8	0
17	Phenotypic and functional translation of IL33 genetics in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 144-157.	2.9	29
18	The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?. <i>ERJ Open Research</i> , 2021, 7, 00768-2020.	2.6	14

#	ARTICLE	IF	CITATIONS
19	Prevalence and predictors of adherence to controller therapy in adult patients with severe/difficult-to-treat asthma: a systematic review and meta-analysis. <i>Journal of Asthma</i> , 2020, 57, 1379-1388.	1.7	22
20	Illness perceptions in difficult-to-treat asthma compared with a depressed psychosis cohort. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 203-205.	1.0	2
21	Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA). <i>Health and Quality of Life Outcomes</i> , 2020, 18, 336.	2.4	10
22	The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: A systematic review and meta-analysis. <i>Respiratory Medicine</i> , 2020, 173, 106156.	2.9	14
23	Clinical utility of fractional exhaled nitric oxide in severe asthma management. <i>European Respiratory Journal</i> , 2020, 55, 1901633.	6.7	83
24	Development and Clinical Application of a Prednisolone/Cortisol Assay to Determine Adherence to Maintenance Oral Prednisolone in Severe Asthma. <i>Chest</i> , 2020, 158, 901-912.	0.8	10
25	Phenotypic and functional translation of IL1RL1 locus polymorphisms in lung tissue and asthmatic airway epithelium. <i>JCI Insight</i> , 2020, 5, .	5.0	26
26	Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study. <i>Thorax</i> , 2019, 74, 806-809.	5.6	18
27	Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 20-34.	10.7	183
28	Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 454-464.	5.6	115
29	Nocturnal temperature-controlled laminar airflow device for adults with severe allergic asthma: the LASER RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-140.	2.8	7
30	Does Continuous Positive Airway Pressure (CPAP) treatment of obstructive sleep apnoea (OSA) improve asthma-related clinical outcomes in patients with co-existing conditions?- A systematic review. <i>Respiratory Medicine</i> , 2018, 143, 18-30.	2.9	30
31	Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 63-72.	3.4	22
32	A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. <i>Trials</i> , 2018, 19, 5.	1.6	26
33	Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. <i>Respiratory Medicine</i> , 2018, 143, 31-38.	2.9	41
34	Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. <i>Respiratory Medicine</i> , 2017, 124, 36-43.	2.9	65
35	Biomarkers of oxidative stress and antioxidants in severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 445-451.	1.0	36
36	Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). <i>BMJ Open</i> , 2016, 6, e011857.	1.9	61

#	ARTICLE	IF	CITATIONS
37	Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. <i>Respiratory Medicine</i> , 2016, 118, 46-52.	2.9	12
38	Fevipirant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 699-707.	10.7	220
39	Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2016, 29, 346-361.	1.4	24
40	Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. <i>Thorax</i> , 2016, 71, 339-346.	5.6	257
41	Dedicated Severe Asthma Services Improve Health-care Use and Quality of Life. <i>Chest</i> , 2015, 148, 870-876.	0.8	100
42	The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. <i>Thorax</i> , 2015, 70, 376-378.	5.6	152
43	Long-Term Safety and Efficacy of Fluticasone/Formoterol Combination Therapy in Asthma. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2013, 26, 190-199.	1.4	26
44	Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1008-1016.	2.9	125
45	Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study. <i>Journal of Asthma</i> , 2013, 50, 529-536.	1.7	102